Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

29 mai 2018

18:00
PASADENA, Calif., May 29, 2018 /PRNewswire-PRWeb/ -- A May 23 article in Medical News Bulletin reports on an analysis of data looking at a possible connection between emotional stress and cavities. The link appears to be connected to the amount of...

12:00
COLD SPRING HARBOR, N.Y., May 29, 2018 /PRNewswire/ -- Neuroscientists at Cold Spring Harbor Laboratory (CSHL) have identified a neural circuit in the amygdala, the brain's seat of emotion processing, that gives rise to anxiety. Their insight has...

10:24
Northwest Biotherapeutics -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L...

09:00
A preliminary study conducted by the National Perinatal Association (NPA) and 4moms shows that using the mamaRoo infant seat with babies affected by Neonatal Abstinence Syndrome (NAS) in the NICU increased their comfort level.  Babies experience NAS...

09:00
TrioxBio Inc., a clinical-stage biopharmaceutical company specializing in the development of drugs to treat diseases and medical conditions related to the pathological overproduction of nitric oxide (NO), today announced that the U.S. Food and Drug...

08:32
The research team behind an emerging immunotherapy for cancer will present interim findings from an ongoing clinical study in patients with brain cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Collaborators...

08:30
PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre® (lurbinectedin, PM1183) in combination...

08:00
Intrexon Corporation , a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Epimeron, Inc., a world-class provider of gene discovery and biosynthetic pathway optimization, today...

08:00
Merchavia Holdings and Investments , an Israeli investment company specializing in early-stage life science sector companies, reports positive results from a successful trial which was conducted Cleveland Clinic, a leading medical center, using...

08:00
A new study published in the American Journal of Health Promotion is the first to demonstrate that a short, intensive workplace wellness intervention can produce sustained improvements in wellbeing. Specifically, the study found that a 2.5-day...

08:00
Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients, today announced that the first patient has been enrolled in the Phase 2 REAKT (Reltecimod E fficacy for Acute Kidney Injury T rial) study. The...

06:11
Recognition by NICE Serves as Global Benchmark for High Quality Healthcare Solutions  Medial EarlySign (http://www.earlysign.com), a leader in machine-learning based solutions to improve non-communicable disease management, today announced that the...

06:00
Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") has been informed that the company's lead innovative product Epidaza® (Chidamide), an oral subtype-selective histone deacetylase (HDAC) inhibitor previously approved for recurrent...

04:01
OliX Pharmaceuticals Inc., a leading developer of RNA interference (RNAi) therapeutics (CEO: Dong-ki Lee, Ph.D.), announced that it received the Phase I clinical trial authorization (CTA) with its anti-scar drug, OLX10010, from Medicines and...

02:26
BerGenBio ASA (OSE:BGBIO) will host a conference call on Monday, 4 June at 8:30 AM CEST to present updated interim clinical and biomarker results from its ongoing Phase II development programme with selective AXL inhibitor bemcentinib. The data will...


28 mai 2018

11:14
Getinge, un fournisseur mondial de premier plan de technologie médicale innovante, annonce aujourd'hui les résultats de l'étude pilote SEMPER FI (Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP...

10:42
Getinge, un fournisseur mondial de technologies médicales innovantes, a annoncé aujourd'hui les résultats de l'étude pilote Amélioration de la survie dans l'infarctus du myocarde étendu avec ischémie persistante à la suite de l'implantation d'un...

10:34
Novartis announced today new real world evidence from the CHAMP-HF registry comparing Entresto® (sacubitril/valsartan) patients to patients not taking Entresto.1 This pre-specified analysis of an interim data cut from the CHAMP-HF registry showed...


25 mai 2018

14:28
Getinge, a leading global provider of innovative medical technology, today announced results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study. The study...

13:16
Nordic Nanovector ASA (OSE: NANO) has received feedback from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer-1 Phase 1b trial with Betalutin®...

10:00
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the presentation of data from two assets in its immuno-oncology portfolio at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). These presentations...

02:00
Approval for multicenter study "TIES-C03" in major university hospitals in Leeds, UK & Umeå, Sweden. OstomyCure AS has achieved an important milestone on the way to making the revolutionary TIES® Solution available to ileostomy patients, a patient...


24 mai 2018

23:15
Q-Pharm, a leading Australian early-phase clinical research organization announced today that in collaboration with the Trade Investment Queensland (TIQ) Japan office, it conducted a high-level seminar in Tokyo, Japan. The seminar held on 17th May,...

21:20
Nobles Medical Technologies II, Inc. (NMT 2) announced today that the 1000th NobleStitchtm EL was performed on a patient who specifically requested the procedure. The patient has been successfully treated using the NobleStitchtm EL suture-based...

19:34
Eisai Inc. and Merck , known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental New Drug Application (sNDA) for lenvatinib for the potential...

15:37
Repair and regeneration capacity of skeletal tissues diminishes with age, often leading to delayed or impaired fracture healing. While the cause of diminished healing capacity is probably driven by a concert of many factors, evidence suggests that...

15:00
The National Organization for Rare Disorders (NORD), the leading independent, nonprofit organization committed to the identification, treatment, and cure of rare disorders, announces the availability of new research grants to support the study of...

13:36
Today, DotLab announces that a new longitudinal study has been initiated at the Yale School of Medicine to validate its non-invasive blood and saliva tests for endometriosis. The study will focus on the test's potential to monitor disease progression...

11:24
Breast cancer survivors are not getting the recommended level of screening, post-surgery, according to a newly-published study in JNCCN ? Journal of the National Comprehensive Cancer Network. The study was led by Kathryn Ruddy, MD, MPH, Director of...

09:00
AbbVie , a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMBRUVICA® (ibrutinib) in...

09:00
Bionomics Limited (ASX:BNO) , a...

08:30
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world data that showed frail patients with non-valvular atrial fibrillation (NVAF) experienced significantly fewer strokes and systemic emboli when treated with...

08:30
The addition of Cxbladder Monitor for bladder cancer surveillance has been shown to enable physicians to reduce the overall number of diagnostic tests being ordered, potentially reducing the total cost of monitoring and reducing complications related...

08:01
Les personnes ayant un IMC de plus de 30 et étant traitées par Saxenda® (liraglutide) pour la gestion du poids ont perdu 8,1 kg (17,9 lb) en moyenne après six mois d'essais cliniques en situation réelle, avec une combinaison de régime et d'exercice....

08:01
People with a BMI of over 30, treated with Saxenda® (liraglutide) for weight management, lost an average of 8.1 kg (17.9 lbs) after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week...

08:00
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies for rare and common malignancies, today announced a clinical supply arrangement with Pharmacyclics through which Pharmacyclics supplies...

07:30
Stellar Biotechnologies, Inc. , a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancer, among other diseases, today announced that third-party trial results have...

07:14
Targovax ASA ("Targovax" or "the Company") (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces the completion of the 32-patient phase I/II clinical trial evaluating TG01 in...

07:00
Significant technology advancements set stage for targeted, multi-generation suppression of disease-transmitting mosquitoes   Oxitec Ltd, a wholly owned subsidiary of Intrexon Corporation , announced that the newest addition to its Friendlytm...

07:00
Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company has completed enrollment in its Phase 2 study of PR022, Realm's...

07:00
Miracor Medical SA announced today the clinical results from the physician-sponsored OxAMI-PiCSO study were published in the EuroIntervention journal and presented at the Hotline session of the EuroPCR conference by Dr. Giovanni Luigi De Maria, MD,...

05:32
Antisense Therapeutics (the "Company" or "ANP") is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-reviewed medical journal, the European...

04:07
New research from Griffith University, Australia, published today in the Journal of Alternative and Complementary Medicine, shows a multispecies-probiotic formulation to improve the quality of life of hay fever patients. Study details  The...

02:00
ECI-006 is safe and well tolerated eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has completed enrolment of the low dose cohort in its...

02:00
People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

00:01
Combining data from electronic health records with results from standardized depression questionnaires better predicts suicide risk in the 90 days following either mental health specialty or primary care outpatient visits, reports a team from the...


23 mai 2018

19:20
CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzenetm-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA...

17:34
Epigen Biosciences, Inc. announced today that it has entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney disease and...

14:18
A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) was presented this week at EuroPCR 2018, an international congress of interventional cardiovascular medicine researchers...

14:00
A research team from NUST MISIS and Pirogov Russian National Research Medical University (RNRMU) has successfully conducted preclinical trials of a new anticancer drug based on magnetite nanoparticles. In the test results, the lifetime of sick mice...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18